Paul Carter is a Senior Director and Staff Scientist in the Antibody Engineering Department at Genentech, Inc. His research interests focus on creating new antibody technologies and applying them to develop future generations of antibody therapeutics.
Carter has published more than 110 scientific publications that together have been cited >17,300 times. He is an inventor or co-inventor on at least 45 issued US patents and 54 published US patent applications.
Carter’s accomplishments in drug development include initiating the antibody humanization program at Genentech. He is a coinventor of 6 antibodies that have entered clinical development including one that later became a commercial product. Carter is a coinventor of “knobs-into-holes” used to create a one-armed antibody and at least 5 bispecific antibodies that have entered clinical development. He is a coinventor of common light chain technology used by several companies for developing at least 6 bispecific antibodies that have entered clinical trials including 1 approved product. He also invented technology for high-level antibody fragment expression in E. coli including a Fab fragment that subsequently became a commercial product.
Carter received a B.A. in Natural Sciences from Cambridge University in 1982 and his Ph.D. in 1986 under Sir Gregory Winter, Ph.D. and F.R.S. at the M.R.C. Laboratory of Molecular Biology in Cambridge. From 1986-1989 he was a Postdoctoral Fellow with Dr. James A. Wells at Genentech.
Carter has over 30 years of experience in biotechnology: Genentech (1986-2000 and 2010-present), Immunex/Amgen (2000-2003), Seattle Genetics (2003-2008) and VLST (2008-2009). His professional experience also includes heading the postdoctoral programs at Genentech (1998-2000), Immunex (2001-2002) and Amgen (2002-2003).
Conference 29 - 31 October • Exhibition & Seminars 29 - 31 October